Home » Stocks » ATAI

ATAI Life Sciences N.V. (ATAI)

Stock Price: $15.50 USD -0.56 (-3.49%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $15.59 +0.09 (0.58%) Jul 30, 7:55 PM
Market Cap 2.36B
Revenue (ttm) 19.88M
Net Income (ttm) -178.63M
Shares Out 152.57M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $15.50
Previous Close $16.06
Change ($) -0.56
Change (%) -3.49%
Day's Open 16.12
Day's Range 14.42 - 16.12
Day's Volume 605,963
52-Week Range 14.42 - 22.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Atai Life Sciences (NASDAQ:ATAI) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments. InnarisBio Inc., as the co...

3 days ago - Benzinga

BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatmen...

4 days ago - GlobeNewsWire

This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:ATAI), the Peter Thiel-backed biotech exploring a host of psychedelic compounds and treatment...

2 weeks ago - Benzinga

CHICAGO, July 15, 2021 /PRNewswire/ --  P alo Santo , the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of 20...

2 weeks ago - PRNewsWire

With the trading day more than halfway over, the broad markets saw a loss across the board.

Other stocks mentioned: CHWY, CLF, NVDA, BODY, EAT, NLSN, OSTK ...
3 weeks ago - 24/7 Wall Street

BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for va...

3 weeks ago - GlobeNewsWire

It's off to a running start.

4 weeks ago - The Motley Fool

Unique insider buys at high levels through the second quarter

Other stocks mentioned: FCBP, MLVF, MPB, PHX
4 weeks ago - GuruFocus

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sect...

1 month ago - Benzinga

The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.

1 month ago - CNBC

Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of ...

1 month ago - New York Post

(Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitaliz...

1 month ago - Reuters

Atai Life Sciences founder on using psychedelics to treat mental illness

YouTube video

Atai Life Sciences, a biotech company that uses psychedelics to treat mental illness, is going public on the Nasdaq Friday. Christian Angermayer, Atai Life Sciences founder, joined "Squawk Box" on Frida...

1 month ago - CNBC Television

BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today ...

1 month ago - GlobeNewsWire

BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the c...

1 month ago - GlobeNewsWire

ATAI Life Sciences N.V. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About ATAI

ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. We founded atai Life Sciences in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooke... [Read more...]

Industry
Biotechnology
IPO Date
Jun 18, 2021
CEO
Florian Brand
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
ATAI
Full Company Profile

Financial Performance

Financial Statements